When Does Pre-IPO Financial Reporting Trigger Post-IPO Legal Consequences?

被引:14
|
作者
Billings, Mary Brooke [1 ]
Lewis-Western, Melissa Fay [2 ]
机构
[1] NYU, New York, NY 10003 USA
[2] Univ Utah, Salt Lake City, UT 84112 USA
关键词
EARNINGS MANAGEMENT; MERITS MATTER; LITIGATION RISK; CASH FLOWS; PERFORMANCE; INFORMATION; VALUATION; QUALITY; IMPACT; ISSUES;
D O I
10.1111/1911-3846.12146
中图分类号
F8 [财政、金融];
学科分类号
0202 ;
摘要
Prior research suggests that the fear of litigation precludes most managers from manipulating earnings in the initial public offering (IPO) setting. Yet, managers' restraint is perhaps unwarranted: research has not yet linked instances of aggressive pre-IPO reporting to increased litigation risk. This paper investigates when aggressive IPO reporting triggers legal consequences. Examining 2,037 IPOs, we find that even when ex post evidence indicates the presence of earnings inflation, litigation is more likely to occur when investors have relied on the suspect earnings during the pricing process. Why might investors rely on some firms' abnormal accruals when valuing the IPO and yet discount the abnormal accruals of other firms? Our analyses suggest that IPO investors incorporate abnormal accrual information into IPO prices insituations where accruals are more likely to reflect information and where other sources of information to help investors make pricing decisions are lacking or are less reliable. In these situations, we find that abnormal accruals do positively correlate with future performance, validating investors' use of this information when pricing these offerings. Yet, when ex post performance reveals that these pre-IPO abnormal accruals were in fact inflated, we find that litigation emerges to allow harmed shareholders to recover losses incurred dating back to the pricing processimportantly, investors are only harmed if they used those abnormal accruals in pricing the IPO. Collectively, our evidence indicates that litigation in response to earnings inflation does indeed surface in the IPO settingbut only when investors need it to settle the score.
引用
收藏
页码:378 / 411
页数:34
相关论文
共 20 条
  • [1] The greater the investor attention, the better the post-IPO performance? A view of pre-IPO and post-IPO investor attention
    Zhao, Yi
    Wang, Nan
    Zhang, Luyang
    Sun, Baiqing
    Yang, Yuchen
    [J]. RESEARCH IN INTERNATIONAL BUSINESS AND FINANCE, 2022, 63
  • [2] Pre-IPO operational and financial decisions
    Babich, V
    Sobel, MJ
    [J]. MANAGEMENT SCIENCE, 2004, 50 (07) : 935 - 948
  • [3] Pre-IPO hype by affiliated analysts: Motives and consequences
    Qian, Yiming
    Shao, Xinjian
    Liao, Jingchi
    [J]. JOURNAL OF CORPORATE FINANCE, 2024, 89
  • [4] Does franchising matter on IPO performance? An examination of underpricing and post-IPO performance
    Ozdemir, Ozgur
    Kizildag, Murat
    [J]. INTERNATIONAL JOURNAL OF CONTEMPORARY HOSPITALITY MANAGEMENT, 2017, 29 (10) : 2535 - 2555
  • [5] Speed and consequences of venture capitalist post-IPO exit
    Paeglis, Imants
    Veeren, Parianen
    [J]. JOURNAL OF CORPORATE FINANCE, 2013, 22 : 104 - 123
  • [6] Who knows what when?: The information content of pre-IPO market prices
    Löffler, G
    Panther, PF
    Theissen, E
    [J]. JOURNAL OF FINANCIAL INTERMEDIATION, 2005, 14 (04) : 466 - 484
  • [7] Supply Chain Portfolio Characteristics: Do They Relate to Post-IPO Financial Performance?
    Schwieterman, Matthew A.
    Goldsby, Thomas J.
    Rungtusanatham, M. Johnny
    Knemeyer, A. Michael
    [J]. TRANSPORTATION JOURNAL, 2018, 57 (04) : 429 - 463
  • [8] VC ownership post-IPO: When, why, and how do VCs exit?
    Basnet, Anup
    Pukthuanthong, Kuntara
    Turtle, Harry
    Walker, Thomas
    [J]. JOURNAL OF FINANCIAL RESEARCH, 2024,
  • [9] The tone and readability of the media during the financial crisis: Evidence from pre-IPO media coverage
    Bhardwaj, Arti
    Imam, Shahed
    [J]. INTERNATIONAL REVIEW OF FINANCIAL ANALYSIS, 2019, 63 : 40 - 48
  • [10] The Role of Pre-IPO Financial Indicators and Intermediaries in Aftermarket Performance and Survival in the US Biopharmaceutical Market
    David R. Williams
    Carlton C. Young
    [J]. Journal of Pharmaceutical Innovation, 2012, 7 : 127 - 139